# The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation

> **NCT05769738** · PHASE3 · UNKNOWN · sponsor: **American University of Beirut Medical Center** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease Exacerbation
- COPD Exacerbation

## Interventions

- **DRUG:** Furosemide
- **DRUG:** Normal saline

## Key facts

- **NCT ID:** NCT05769738
- **Lead sponsor:** American University of Beirut Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769738, "The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05769738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*